Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Vanda Pharmaceuticals (VNDA) Gross Profit: 2010-2025

Historic Gross Profit for Vanda Pharmaceuticals (VNDA) over the last 16 years, with Sep 2025 value amounting to $53.3 million.

  • Vanda Pharmaceuticals' Gross Profit rose 18.19% to $53.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $200.3 million, marking a year-over-year increase of 12.09%. This contributed to the annual value of $187.5 million for FY2024, which is 5.41% up from last year.
  • Per Vanda Pharmaceuticals' latest filing, its Gross Profit stood at $53.3 million for Q3 2025, which was up 6.92% from $49.9 million recorded in Q2 2025.
  • In the past 5 years, Vanda Pharmaceuticals' Gross Profit registered a high of $63.3 million during Q3 2021, and its lowest value of $35.8 million during Q3 2023.
  • Moreover, its 3-year median value for Gross Profit was $46.5 million (2025), whereas its average is $46.8 million.
  • Its Gross Profit has fluctuated over the past 5 years, first crashed by 39.40% in 2023, then climbed by 26.15% in 2024.
  • Vanda Pharmaceuticals' Gross Profit (Quarterly) stood at $61.8 million in 2021, then dropped by 5.73% to $58.2 million in 2022, then fell by 28.21% to $41.8 million in 2023, then increased by 21.01% to $50.6 million in 2024, then increased by 18.19% to $53.3 million in 2025.
  • Its last three reported values are $53.3 million in Q3 2025, $49.9 million for Q2 2025, and $46.5 million during Q1 2025.